Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22.

James A KarlowskyMark G WiseMeredith A HackelDavid A SixTsuyoshi UeharaDenis M DaigleDaniel C PevearGreg MoeckDaniel F Sahm

Published in: The Journal of antimicrobial chemotherapy (2024)

Cefepime-taniborbactam exhibited potent in vitro activity against Enterobacterales and P. aeruginosa, and inhibited most carbapenem-resistant isolates, including those carrying serine carbapenemases or NDM/VIM MBLs.

Keyphrases

pseudomonas aeruginosa
klebsiella pneumoniae
cystic fibrosis
staphylococcus aureus
randomized controlled trial
study protocol
biofilm formation
clinical trial
acinetobacter baumannii
escherichia coli
multidrug resistant
anti inflammatory
candida albicans